The cytotoxic evaluation of the complex of CCB-2 compound was also determined by testing against two different model of breast cancer: TNBC and HER-2 positive cancer cells, as well as tested in non-cancerous cells to determine the selectivity of these compounds. Here, ERBB2 is linked to breast carcinoma.